In the head-to-head SURMOUNT-5 trial, tirzepatide achieved 20.2% mean weight reduction compared to 13.7% with semaglutide at 72 weeksa difference of 6.5 percentage points
Subsequently, this led to increased adipocyte apoptosis and chemokine production and decreased adiponectin expression, which promoted macrophage infiltration and M1 polarization in eWAT, thus exacerbating eWAT inflammation and ultimately facilitating serum and distal heart inflammation
Semaglutide Both tirzepatide and semaglutide are powerful tools, but they act slightly differently: Semaglutide A GLP-1 receptor agonist Weekly injection (brand names Ozempic for diabetes, Wegovy for weight loss) Helps many patients achieve 1015% weight loss with lifestyle support Tirzepatide Dual-action: mimics GLP-1 and GIP (another metabolic hormone) Weekly injection (brand names Mounjaro and Zepbound) Some clinical trials show average weight loss of 1520% or more Because tirzepatide acts on two hormone pathways, it may have enhanced benefits for blood sugar control and weight reduction
Tirzepatide (Mounjaro, Zepbound) : A dual GLP-1/GIP receptor agonist approved for diabetes and weight management
Jesse Richards, director of obesity medicine and assistant professor of medicine at the OU-TU School of Community Medicine, said the study was inspired by his conversation with Dr